We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+31.6%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$1.84B
AUM Growth
+$450M
Cap. Flow
+$71.6M
Cap. Flow %
3.89%
Top 10 Hldgs %
79.12%
Holding
28
New
5
Increased
6
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$44.3M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$32.5M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$27.1M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$26.8M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$26.8M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$26.2M
2
CELG
Celgene Corp
CELG
+$21.2M
3
INCY icon
Incyte
INCY
+$17.5M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$16.9M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.92M

Sector Composition

Rank Sector Weight
1 Healthcare 86.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
26
DELISTED
Medicines Co
MDCO
– –
-302,993
Closed -$9.32M
DNDN
27
DELISTED
DENDREON CORPORATION
DNDN
– –
-1,014,800
Closed -$4.18M
TSRX
28
DELISTED
TRIUS THERAPEUTICS INC COM STK (DE)
TSRX
– –
-280,000
Closed -$2.27M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2013 Portfolio in Review

As of Q3 2013, BB Biotech held 28 positions worth $1.84B, up 32% from $1.39B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

BB Biotech deployed $71.6M of net new capital in Q3 2013, opening 5 new positions and adding to 6 existing holdings. Its largest new stake was PHARMACYCLICS INC: 399,030 shares worth $55.2M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier.

On the sell side, the largest reduction was ONYX PHARMACEUTICALS INC, an estimated $26.2M trimmed.

  • BB Biotech's largest Q3 2013 buy was PHARMACYCLICS INC: 399,030 shares worth $55.2M.
  • BB Biotech added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013, an estimated $32.5M increase.
  • BB Biotech's biggest Q3 2013 reduction was ONYX PHARMACEUTICALS INC, cutting an estimated $26.2M.
  • BB Biotech fully exited BioMarin Pharmaceuticals in Q3 2013, selling an estimated $9.92M.
  • BB Biotech's ten largest holdings make up 79% of its $1.84B portfolio in Q3 2013.
  • BB Biotech opened 5 new positions and closed 4 in Q3 2013.
  • BB Biotech's portfolio value rose 32% quarter-over-quarter to $1.84B.

Based on BB Biotech's 13F filing for Q3 2013, filed 12 Nov 2013.